Phase 3 study demonstrates efficacy of oxymetazoline for blepharoptosis, suggesting a safe treatment option.
Fourteen days of OMZ 0.1% treatment significantly increased MRD-1 versus placebo. There was no loss of effect after 6 months of treatment and no significant safety concerns.
No takes yet. Share an insight, caveat, or question.
Ishikawa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: